Antibody-enhancing technologies
Kyowa Kirin owns the proprietary antibody-enhancing technologies, POTELLIGENT® and COMPLEGENT®.
POTELLIGENT® technology
Antibodies are composed of “sugar chains”. Among these, a sugar chain called “fucose” is very important for ADCC activity. We discovered that the removal of “fucose” from an antibody led to tremendous enhancement of ADCC activity in this antibody when compared with other antibodies. This is the core of POTELLIGENT® technology.
COMPLEGENT® technology
Other than ADCC activity, antibodies have another biological defense system: CDC activity. Using "isotype-chimeric" technology which combines characteristics of 2 IgG (lmmunoglobulin G) isotype molecules, we succeeded in creating an "isotype-chimeric" antibody with enhanced CDC activity. This is the core of COMPLEGENT® technology.
AccretaMab® technology
Antibodies created by combining our antibody enhancing technologies, POTELLIGENT® and COMPLEGENT®, are called AccretaMab®. AccretaMab® is an antibody that has the combination of enhanced ADCC activity and CDC activity.